A bank just booked the highest annual profit in the history of Bangladesh’s private sector lending — and on the same exchange, textile and fuel-and-power stocks are still trading more than a third below where they started the year. That is the DSE on April 30, 2026. BRAC Bank reported Tk 2,251 crore in FY2025 profit, a 57% jump that made it the first local private lender to cross the Tk 2,000 crore threshold. Textile stocks remain down 33.7% year-to-date. Fuel & Power: down 34.2%.
A single energy crisis. Two completely different income statements.
That bifurcation is the whole story of the April 30 earnings cluster, and it is sharper than the headline numbers suggest. The DSEX added 8 points to close at 5,309 on April 28, turnover crossed Tk 1,000 crore for the first time in three sessions, and the buying was almost entirely concentrated in the names that had something good to announce. The names that did not are not selling off — they have already sold off. They are now pricing the next leg.
Here is what each sector reported, and what it tells you about Q2.
Banking: The Remittance Dividend Compounds
Banking is not just outperforming on April 30 — it is being repriced. The sector P/E ratio sits at 9.2x against a three-year average of 7.0x, and the premium is being earned, not borrowed. Earnings have grown roughly 10% annually for three years. Revenue growth, more modest at 6.1%, suggests the margin story is doing the heavy lifting.
BRAC Bank’s H1 2025 alone delivered Tk 905 crore on investment gains — a sign that banks are converting a deposit surge into trading and treasury income while the broader economy slows. Remittance inflows hit Tk 331 billion in just the first 26 days of April, fuel for credit expansion that energy-stressed sectors cannot access. Pubali Bank, Al-Arafah, and UCB results released across the late-April window largely confirmed the pattern: deposits up, fee income up, NIM holding.
The names that led on April 28 — BRAC Bank, Prime Bank, National Bank, City Bank — are also the ones with the cleanest earnings releases. That is not a coincidence. It is what the cycle looks like when remittance flows offset lending headwinds.
What none of those banks tell you is what happens when their textile and energy-sector borrowers start showing strain. That conversation is in the next set of results, not this one.
Insurance: Quiet Outperformance Nobody Is Talking About
If banking is loud, insurance is the trade that is working without making noise. General insurance accounted for 14.2% of total April market turnover. Sector market cap rose to Tk 14,458 crore in January 2026 from Tk 12,788 crore in December — a 13% expansion in a single month, before the April rally even started.
Standard Insurance, Reliance Insurance, Pioneer Insurance, and Phoenix Insurance led the gains. Life insurance is participating, more moderately. The mechanism is simple: inflation lifts premium income, claims experience has not yet deteriorated, and insurance valuations have inflation hedging built into them the way bond portfolios do not.
The catch is that insurance stocks are notoriously volatile around Q-end disclosure dates — and the Q3 March-end statements being reviewed at April 30 board meetings will test whether the rally has fundamentals beneath it or just float.
Pharmaceutical: Volume Up, Margin Down, Verdict Pending
Pharma is the sector where the numbers and the narrative diverge most sharply. Bangladesh meets 98% of domestic finished-form drug demand locally — 213 companies operating in a self-sufficient market. Sector growth is averaging 12% annually. Turnover share is a healthy 11.8%.
So why is pharma classified as margin-compressed?
Because the price line is frozen and the cost line is not. Government price controls — the same regulation that protects access — prevents margin expansion when input costs rise. And input costs are rising sharply: energy is feeding directly into production expense, packaging, distribution, and cold-chain. Square Pharma’s defensive premium during sell-offs is starting to compress because the volume story can no longer hide the per-unit math.
The April 30 board meetings reviewing FY2025 audited financials will not surface this fully — full-year numbers will look fine. The Q3 unaudited statements ending March 31 are the ones to read carefully. That is where the energy crisis first shows up in the operating margin line.
Textile and Fuel & Power: The Cost-Side Casualties
Textile is down 33.7% YTD. Fuel & Power is down 34.2%. These are not minor pullbacks. These are sector-level recessions priced into equity values — and they are pricing rationally.
Bangladesh is the world’s second-largest textile exporter, and the sector represents roughly 85% of total export earnings. It is also the most energy-intensive industry on the exchange. With global fuel prices elevated by Middle East tensions and domestic energy supply pressure already exposed, textile producers are paying more to make less competitive product. The fuel price hike to Tk 115 diesel and Tk 140 octane made the squeeze structural, not seasonal.
Fuel & Power itself is now the most regulatory-exposed sector on the DSE — caught between Tk 52,300 crore in unpaid power bills and pricing decisions made above the company’s pay grade.
Cement, ceramics, and any cyclical with imported inputs are next in the queue.
What the April 30 Cluster Actually Means for Q2
The earnings divergence on April 30 is not a one-quarter event. It is the first quarter where the energy crisis showed up cleanly in the operating line of every sector at once. Banking and insurance absorbed it through balance-sheet flows. Pharma absorbed it through volume. Textile and Fuel & Power could not absorb it at all.
The Q2 results — May and June board meetings reviewing the March-end quarter — will tell you whether pharma joins the second group. If the margin compression confirms, the defensive bid that has held DSEX above 5,200 loses one of its three legs.
A bank just made record profit. A textile sector is bleeding. The same energy bill is on both their desks. The only question that matters now is which side pharma lands on by July.